Chiusura precedente | 0,3128 |
Aperto | 0,3400 |
Denaro | 0,0000 x N/D |
Lettera | 0,0000 x N/D |
Min-Max giorno | 0,3374 - 0,3400 |
Intervallo di 52 settimane | 0,3374 - 0,3400 |
Volume | |
Media Volume | N/D |
Capitalizzazione | 78.841 |
Beta (5 anni mensile) | 1,03 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -2,1370 |
Prossima data utili | 11 ago 2022 |
Rendimento e dividendo (forward) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
ARLINGTON, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it will report second quarter 2022 financial results on Thursday, August 11, 2022. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET. The dial-i
ARLINGTON, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that management will participate in the following virtual healthcare investor conferences in August 2022: 2022 Wedbush PacGrow Healthcare ConferenceDate: Wednesday, August 10, 2022Company management will participate in a fireside ch
ARLINGTON, Mass., July 22, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 40,000 shares of Kala Pharmaceuticals common stock to the new employee. The stock options were granted on July 18, 2022. The gra